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Abstract  28 
Osteoarthritis is a degenerative joint disease for which there are no disease-modifying drugs.  29 
It is a leading cause of disability in the UK.  Increasing age and obesity are both major risk 30 
factors for osteoarthritis and the health and economic burden of this disease will increase in 31 
the future.  Focusing on compounds from the habitual diet that may prevent the onset or 32 
slow the progression of osteoarthritis is a strategy that has been under-investigated to date.  33 
An approach that relies on dietary modification is clearly attractive in terms of risk/benefit 34 
and more likely to be implementable at the population level.    However, before undertaking 35 
a full clinical trial to examine potential efficacy, detailed molecular studies are required in 36 
order to optimise the design.  This review focuses on potential dietary factors that may 37 
reduce the risk or progression of osteoarthritis, including micronutrients, fatty acids, 38 
flavonoids and other phytochemicals.  It therefore ignores data coming from classical 39 
inflammatory arthritides and nutraceuticals such as glucosamine and chondroitin.  In 40 
conclusion, diet offers a route by which the health of the joint can be protected and 41 
osteoarthritis incidence or progression decreased.  In a chronic disease, with risk factors 42 
increasing in the population and with no pharmaceutical cure, an understanding of this will 43 
be crucial. 44 
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Introduction: 49 
Osteoarthritis (OA) is a degenerative joint disease characterised by degradation of articular 50 
cartilage, thickening of subchondral bone and osteophyte formation.  Incidence and 51 
prevalence of OA has been difficult to assess, in part because of heterogeneity in definitions 52 
of the disease.  A recent meta-analysis suggested that overall prevalence of OA at different 53 
anatomical sites was 23.9% (knee), 10.9% (hip) and 43.3% (hand) although only the 54 
prevalence of knee OA showed a gender difference between women and men (27.3% and 55 
21% respectively)(1).   56 
 57 
OA is a leading cause of disability in the UK.  A recent survey(2) found 8.5 million people in 58 
the UK with osteoarthritis, with 71% of these in constant pain.  There are no effective 59 
disease-modifying drugs to treat OA and drugs that relieve pain are often insufficient. Joint 60 
replacement is offered to patients at end-stage disease with 66,436 hip and 77,578 knee 61 
replacements due to OA performed in the UK in 2011(3).   62 
 63 
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Two major risk factors for OA are increasing age, (most affected patients are >45 years of 64 
age and the greatest morbidity is seen in patients >60 years of age)(4) and increasing 65 
obesity(5).  With changing demographics, OA is an increasing public health and economic 66 
burden.  The economic costs of OA in the UK are largely unknown, but direct costs have 67 
been estimated at approximately £1 billion per year.  With inclusion of indirect costs, 68 
estimates from the USA range up to £8 billion per year(6). 69 
 70 
While the ability to slow or stop the progression of OA would have individual and population 71 
level benefits, few pharmaceutical companies maintain OA as a disease area.  This is in part 72 
because there is no precedent.  Further, OA generally progresses slowly, and there are no 73 
current validated biomarkers for cartilage destruction (joint space narrowing, assessed on X-74 
ray, is the only FDA (Food and Drug Administration) approved end point in a clinical trial)(7).  75 
Issues of toxicity, in a disease which is not life-threatening, can also make drug development 76 
problematic.  It is possible to overcome at least some of these issues by selection of the 77 
patient group (where particular sub-groups are known to progress more rapidly), and by 78 
establishing the dose of drug that gives efficacy within the target tissue (i.e. cartilage)(8).   79 
 80 
Focusing on compounds from the habitual diet that may prevent the onset or slow the 81 
progression of OA is an alternative strategy.  Since in essence, all of the population can be 82 
viewed as at risk for the development of OA in old age, an approach that relies on dietary 83 
modification is clearly more attractive in terms of risk/benefit and more likely to be 84 
implementable.  However, detailed molecular studies ahead of a full clinical trial are required 85 
in order to design trials optimally that will examine potential efficacy. 86 
 87 
There are currently limited data on the inter-relationship between diet and OA.  Data come 88 
from a variety of studies:  in vitro cell and tissue explant models, animal models, 89 
epidemiological associations, and intervention trials.  There is a large variability between 90 
studies, e.g. in animal models, a dietary intake approach would be optimal in order to relate 91 
to human exposure, but some studies use intra-articular injection and/or concentrations not 92 
achievable through the diet.  The intervention trials conducted to date have many different 93 
designs, number of patients, time length and outcome measures, often with too few patients 94 
and of short duration.  There is a need for better quality data before dietary advice can be 95 
given. However clinical trials in osteoarthritis are expensive and it is not clear who will or 96 
should fund them. 97 
 98 
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This brief review focuses predominantly on potential dietary factors than may reduce the risk 99 
or progression of the disease.  It focuses only on osteoarthritis, mainly ignoring data coming 100 
from more overtly inflammatory arthritides.   101 
 102 
Two pertinent ‘nutraceuticals’ will not be discussed, but should be mentioned:  glucosamine 103 
and chondroitin.  Glucosamine is a sugar and precursor for glycosaminoglycan and therefore 104 
proteoglycan biosynthesis.  Chondroitin is a glycosaminoglycan, a form of which is found in 105 
aggrecan, the major proteoglycan in cartilage.  Hydrochloride and sulphate salts of both 106 
glucosamine and chondroitin have been extensively examined in laboratory models and 107 
clinical trials.  The efficacy of these compounds remains controversial, but most recent 108 
analyses appears to indicate that high-grade preparations of chondroitin sulphate and 109 
glucosamine sulphate, may have efficacy in osteoarthritis(9-13).   110 
 111 
Micronutrients  112 
Vitamin C 113 
In prospective studies examining micronutrient intakes, the Framingham study identified a 114 
protective association between higher intake of vitamin C and the progression of 115 
radiographic knee OA(14) and a higher vitamin C intake was  also be associated with lower 116 
risk of knee pain(14; 15).  However a longitudinal study showed no protective effect of vitamin 117 
C supplements  on the progression of knee OA, though in multivariate analyses vitamin C 118 
supplements were beneficial in preventing the development of knee OA(16).  In healthy 119 
subjects vitamin C intake has been associated with reduced risk of bone marrow lesions on 120 
magnetic resonance imaging(17).  In these publications vitamin C has been viewed simply as 121 
an antioxidant, but it should not be forgotten that vitamin C is a co-factor enabling the proline 122 
and lysine hydroxylation essential for correct collagen biosynthesis.  It also has effects on 123 
regulating the expression and translation of collagen, a major component of many 124 
connective tissues including cartilage and bone(18).  Animal model data (all from the guinea 125 
pig) are conflicting.  Early studies showed that dietary ascorbate decreased pathology in 126 
surgically induced osteoarthritis(19).  In a further study additional ascorbate in the drinking 127 
water showed a protective effect on spontaneous cartilage lesions, but no effect on 128 
pathology post-surgery(20).  Most recently ascorbate supplementation increased disease 129 
severity in spontaneous osteoarthritis(21).   130 
 131 
Vitamin E 132 
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The Framingham study identified a weak protective association between higher intake of 133 
vitamin E and the progression of radiographic knee OA(14).  A study examining tocopherol 134 
isoforms and radiographic knee OA suggested complex associations(22) and intervention 135 
trials of vitamin E have to date been contradictory(23).  In vitro data in chondrocytes are 136 
sparse, but a recent study suggests that vitamin E protects against hydrogen peroxide-137 
induced changes in extracellular matrix gene expression(24). 138 
 139 
Vitamin D 140 
Vitamin D has multiple functions in the musculoskeletal system, particularly in bone health 141 
and pathologies(25).  Many studies have explored the association between vitamin D levels 142 
and OA.  Recent systematic review suggests that low serum concentrations of 25-143 
hydroxyvitamin D are associated with increased radiographic progression of OA, but 144 
associations are weaker with symptoms of disease(26).  A recent longitudinal study 145 
demonstrated the converse, that moderate vitamin D deficiency predicts both knee and hip 146 
pain, independent of structural change(27).  However, a recent 2 year intervention trial 147 
showed no decrease in knee pain or structural change in patients with knee OA, with knee 148 
function significantly worse following vitamin D intervention(28).  Further intervention trials are 149 
ongoing(29).  Vitamin D supplementation in a rat post-surgical model of osteoarthritis showed 150 
a protective effect during the early phase of the disease, but not during the later phase(30).  151 
However, this was scored using condyle width, an unusual method.  Interestingly vitamin D 152 
receptor-deficient mice showed aggravated inflammation and cartilage damage when 153 
crossed into a TNF transgenic model(31). 154 
 155 
Other micronutrients 156 
In a Japanese population (ROAD, Research on Osteoarthritis Against Disability), low 157 
habitual vitamin K intake was the only dietary factor associated with the increased 158 
prevalence of radiographic knee OA in a cross-sectional study(32).  This supports data from 159 
US cohorts where low vitamin K was associated with OA in the hand and knee(33; 34). 160 
However, a further study, using minimum joint space width and osteophytosis as variables 161 
showed an association of vitamins K, B1, B2, B6 and C with the former and vitamins E, K, 162 
B1, B2, niacin (B3) and B6 with the latter, both in women only(35).  Vitamin K is an essential 163 
co-factor for the formation of gamma-carboxyglutamic acid (Gla) residues, and Gla-164 
containing proteins include osteocalcin and matrix Gla protein (MGP), both expressed in the 165 
skeleton. Vitamin K regulates mineralisation in both bone and cartilage(36).  Polymorphisms 166 
in the MGP gene have been associated with hand osteoarthritis(37), and serum levels of 167 
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undercarboxylated osteocalcin maybe associated with synovitis in knee osteoarthritis(38).  168 
Niacinamide, a form of vitamin B3, has been examined in a pilot scale clinical study of 169 
osteoarthritis and reported to show improvements at 12 weeks(39). 170 
An association between dietary magnesium intake and knee OA was demonstrated in the 171 
Johnston County Osteoarthritis Project, but this varied with ethnicity(40).  This is supported by 172 
data from the Twins UK registry where discordant twin pair analysis showed a decrease in 173 
magnesium in co-twins with OA(41).  Selenium has been implicated the osteoarthropathy of 174 
Kashin-Beck disease; meta-analysis of supplementation studies supports the benefit of 175 
supplementation in children, but highlights the low quality of methodology(42). 176 
 177 
Lipid metabolism 178 
Recent studies have suggested that osteoarthritis may be part of metabolic syndrome(43).  179 
Alterations in lipid metabolism may be key to this, with population based  studies suggesting 180 
that serum cholesterol is a risk factor for osteoarthritis (reviewed in(44)).  Population studies 181 
also suggest that statin use is associated with a reduction in osteoarthritis incidence and /or 182 
progression(45; 46), but studies of pain and function in patients with osteoarthritis have shown 183 
no association(47).  This area therefore remains controversial.  It has been reported that high 184 
levels of fat and fatty acids are found in osteoarthritic joint tissues and that this is associated 185 
with pathology(48; 49).  n-3 polyunsaturated fatty acids (PUFA), but not n-6 PUFA were found 186 
to be associated with specific loss of cartilage in the MOST (Multicenter Osteoarthritis Study) 187 
population of people at risk of osteoarthritis(50).  In healthy individuals, consumption of 188 
saturated fatty acids or n-6 PUFA (but not n-3 PUFA) were associated with an increased risk 189 
of bone marrow lesions(51; 52).  In animal models, a high fat diet accelerated progression of 190 
osteoarthritis(53), whilst n-3 PUFA reduced disease(54).  Studies in isolated chondrocytes 191 
showed that n-3 PUFA inhibited IL-1 induced MMP3, MMP13, ADAMTS4, ADAMTS5 and 192 
COX2 (MMP, matrix metalloproteinase; ADAMTS, a disintegrin and metalloproteinase 193 
domain with thrombospondin motifs; COX, cyclooxygenase) expression, whilst n-6 PUFA 194 
had no effect(55; 56).  A small improvement in osteoarthritis in dogs was seen with fish oil 195 
supplementation(57; 58).  Interestingly, a supplement rich in fish oil, Phytalgic, was shown to 196 
improve function and pain in osteoarthritis patients (59), though the design of this trial has 197 
been criticised(60). 198 
 199 
Diet-derived bioactives 200 
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Typically, foods contain multiple bioactive compounds and these can impact upon many 201 
biological pathways(61).  Diet-derived bioactives can be classified into several groups e.g. 202 
flavonoids (and related compounds), carotenoids, plant sterols, glucosinolates and others(62).  203 
 204 
Flavonoids 205 
Flavonoids are polyphenols and include flavan-3-ols, flavonols, flavones, isoflavones, 206 
flavanones and anthocyanins.  More than 6000 different flavonoids have been found and 207 
they are widely distributed in plants, with several hundred found in edible plants(63; 64).   208 
 209 
Flavonols 210 
Flavonols are found in many foods and are exemplified by quercetin, myricetin and 211 
kaempferol(64).  Quercetin and kaempferol showed no activity against IL-1-induced MMP-13 212 
levels in SW1353 chondrosarcoma cells(65).  However, Lay et al report that quercetin is able 213 
to block aggrecan loss from articular cartilage potentially via inhibition of ADAMTS4 and 214 
ADAMTS5(66) and Lee et al show that myricetin can inhibit IL-1 (interleukin-1) induction of 215 
MMP-1 from a synovial cell line(67). 216 
 217 
Flavones 218 
In fruit and vegetables, flavones are found in celery and parsley, mainly luteolin and 219 
apigenin.  In the skin of citrus fruit, polymethoxylated flavones are also found e.g. tangeretin, 220 
nobiltein and sinensetin(64).  Luteolin and nobiletin have been shown to inhibit aggrecanases 221 
ADAMTS-4 and ADAMTS-5, both in vitro(68; 69) and in vivo(68).  Luteolin appears to be 222 
selective as a better ADAMTS than MMP inhibitor(69), it also has anti-inflammatory activity 223 
which could play a role in chondroprotection(70).  Nobiletin, tangeretin and sinensetin all 224 
repress the IL-1 induction of MMP-9 in synovial cells, with nobiletin also active in 225 
chondrocytes(71).   Apigenin was shown to be a potent inhibitor of IL-1-induced MMP-13 226 
expression in SW1353 chondrosarcoma cells, potentially via AP1 and the JAK/STAT 227 
pathway, with no activity against NFkappaB(65).  It has also been shown to block IL-1-228 
induced GAG (glycosaminoglycan) release(65) and HA (hyaluronan) release(72) from cartilage 229 
explants in vitro.   230 
 231 
Flavan-3-ols 232 
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These exist as both monomer (catechins) and polymer (proanthocyanidins) forms(64).  Green 233 
tea polyphenols were shown to be effective in a model of inflammatory arthritis(73).  234 
Catechins from green tea (and also present in other foods including dark chocolate) can 235 
inhibit cartilage degradation in vitro, particularly those containing a gallate ester(74).   236 
Epigallocatechin gallate (EGCG) and epicatechin gallate (ECG) have been shown to be 237 
effective (submicromolar) inhibitors of ADAMTS-4 and ADAMTS-5 aggrecanase activity, 238 
indeed significantly more than their ability to inhibit MMP-1 and MMP-13 collagenase 239 
activity(75).  Other anti-inflammatory activities have been described (e.g.(76)) that suggests 240 
promise in osteoarthritis (reviewed in(77)), but no human clinical trials have been performed to 241 
date. 242 
Whilst not a diet-derived bioactive, Flavocoxid, a mixture of baicalin (a flavone) from 243 
Scutellaria baicalensis and catechins from Acacia catechu, is marketed as Limbrel, a 244 
‘medical food’ which inhibits cyclooxygenase-2 and 5-lipoxygenase(78).  An assessment of 245 
the major catechins from Acacia catechu suggests that they are predominantly those 246 
described above found in green tea(79).  Small clinical trials have suggested that Limbrel 247 
shows efficacy in OA (e.g.(80)), but recently severe liver toxicity has been described in some 248 
patients(81).  249 
A grape seed proanthocyanidin extract is protective in the monosodium iodoacetate (MIA) 250 
model of osteoarthritis in the rat, showing chondroprotection and decreased pain(82).  251 
Specifically, procyanidin B3 abrogates cartilage destruction and heterotopic cartilage 252 
formation in a surgical model of osteoarthritis in the mouse(83).  It was shown to block IL-1 253 
repression of matrix gene expression in vitro and also decrease iNOS (inducible nitric oxide 254 
synthase) in vitro and in vivo(83). 255 
Another mixture not derived from the diet, Pycnogenol is a pine bark extract rich in 256 
procyanidins(84).  It has been reported to inhibit NFkappaB activation and the activity of some 257 
MMPs(85; 86).  Three small clinical trials have been performed in osteoarthritis with positive 258 
outcomes reported (e.g.(87; 88)).  However, a Cochrane review of Pycnogenol in chronic 259 
diseases (including osteoarthritis) stated that it was not possible to reach definite 260 
conclusions on either efficacy or safety of Pycnogenol(89). 261 
 262 
Anthocyanins 263 
Anthocyanins are responsible for the red/blue pigmentation in fruits and vegetables(64).  To 264 
date most studies have been performed using fruit juices or extracts which are rich in 265 
anthocyanins.  A recent clinical trial examined tart cherry juice in patients with knee 266 
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osteoarthritis(90).  No difference in disease scores compared to placebo was uncovered, but 267 
hsCRP (high sensitivity C-reactive protein) was significantly lowered and this was associated 268 
with decreased score(90).  Pomegranate juice or extracts, which have been reported to 269 
contain anthocyanins and many other flavonoids including flavanols, have been shown to 270 
inhibit IL-1-induced MMP expression in chondrocytes via inhibition of MAP kinases and 271 
NFkappaB(91-93).  Such extracts also show efficacy in the MIA model of osteoarthritis in 272 
mice(94).  Raspberry extract(95) and red orange extract(96) have also been reported to have 273 
some efficacy in vitro and in vivo. 274 
 275 
Isoflavones 276 
Isoflavones are diphenolic compounds with structural similarity to estrogens, and are 277 
consequently referred to as phytoestrogens.  They are found mainly in legumes and soya is 278 
a major source of isoflavones in the diet(64).  Data in chondrocytes show that one isoflavone, 279 
genistein, reduces the production of inflammatory molecules like COX-2 and NO (nitric 280 
oxide)(97).  Extracellular matrix synthesis in cartilage may increase or decrease, potentially 281 
with increasing dose(98; 99).  In the rat inflammatory collagen-induced arthritis model, soy 282 
protein appears to be protective(100), however, no significant effect of soy intake was 283 
measurable on osteoarthritis severity in Cynomolgus monkeys(101).  One human study 284 
suggested beneficial effects of soy protein supplementation on function, symptoms and 285 
biochemical markers of osteoarthritis, particularly in men(102). 286 
 287 
Flavanones 288 
Flavanones are present in the diet at high concentrations only in citrus fruits including 289 
naringenin from grapefruit, hesperetin from oranges and eriodictyol from lemons(64).  No 290 
effect was seen for naringenin on IL-1-induced MMP-13 production in SW1353 291 
chondrosarcoma cells(65).  However, hesperetin, its glycoside hesperidin or its dervatives, 292 
show efficacy in inflammatory models of arthritis(103-105).  Red orange juice extract showed 293 
repression of inflammatory molecules in chondrocytes as mentioned above(96). 294 
 295 
Carotenoids 296 
Beta-carotene is the most widely known carotenoid and is a precursor to vitamin A(106).  297 
Vitamin A and its derivatives, retinoids, are known to have profound effects on cartilage and 298 
the skeleton and may contribute to osteoarthritis(107).  The Framingham study identified a 299 
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weak protective association between intake of β-carotene and the progression of 300 
radiographic knee OA(14).  A case-control study in the Johnston Couny Osteoarthritis Project 301 
examined the association between serum levels of several carotenoids (lutein, zeaxanthin, 302 
beta- cryptoxanthin ,lycopene, alpha-carotene and beta-carotene) and osteoarthritis(108).  303 
People with high levels of lutein or beta-cryptoxanthin were less likely to have knee 304 
osteoarthritis, whilst those with high levels of trans-beta-carotene or zeaxanthin were more 305 
likely to have knee osteoarthritis.  Similarly, a cross-sectional study in a Japanese population 306 
with radiographic knee osteoarthritis examined the association between serum levels of 307 
several carotenoids (lutein, zeaxanthin, cantaxanthin, cryptoxanthin, lycopene, alpha-308 
carotene and beta-carotene) and osteoarthritis, but found nothing significant(109).  It is worth 309 
noting that there is evidence that beta-cryptoxanthin is associated with a decreased risk of 310 
inflammatory arthritis e.g.(110).  In healthy, middle-aged people, lutein and zeaxanthin intake 311 
was associated with decreased risk of cartilage defects on MRI and beta-cryptoxanthin 312 
intake was inversely associated with tibial plateau bone area(17). 313 
 314 
Plant sterols 315 
As discussed above, there is a positive association between serum cholesterol and 316 
osteoarthritis, with statin use appearing to show efficacy in disease incidence and/or 317 
progression.  Intake of plant phytosterols/stanols significantly reduce LDL cholesterol and 318 
total cholesterol in intervention trials(111; 112) and of the three phytolsterols tested, 319 
(stigmasterol, sitosterol and campesterol), stigmasterol bound best to chondrocyte 320 
membranes(113).  It inhibited IL-1 induced MMP and ADAMTS4 expression, though had no 321 
effect on ADAMTS5, potentially via its ability to inhibit NFkappaB activation(113).  Intra-322 
articular injection of stigmasterol was shown to suppress MMP expression and reduce 323 
cartilage degradation in a rabbit anterior cruciate ligament transection (ACLT) model of 324 
osteoarthritis(114). 325 
 326 
Glucosinolates 327 
Glucosinolates are found in cruciferous vegetables and are the precursors of 328 
isothiocyanates.  Broccoli is rich in glucoraphanin, and when the vegetable is chopped or 329 
chewed, it is exposed to the action of an enzyme myrosinase to yield sulforaphane, the 330 
isothiocyanate.  In chondrocytes, sulforaphane was initially shown to decrease shear stress-331 
induced apoptosis(115).  More recently it has been shown to exhibit pro-survival and anti-332 
apoptotic activities when cell death is induced by a variety of stimuli(116).  Sulforaphane has 333 
been shown to block IL-1 and TNFalpha induction of MMP-1 and -13 expression, as well as 334 
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PGE2 (prostaglandin E2) and NO in chondrocytes(117) and inhibit cartilage degradation in 335 
vitro(118).  Later work showed that it was effective in inhibiting expression of ADAMTS-4 and -336 
5, and abrogating cartilage destruction in the ‘destabilisation of the medial meniscus’ model 337 
of osteoarthritis in the mouse, acting as a direct inhibitor of NFkappaB(119).  338 
 339 
Resveratrol 340 
Resveratrol is a plant-derived phenol of the stilbenoid class, found at high concentrations in 341 
the skin of red grapes and in red wine.  It has come to the fore as an activator of the histone 342 
deacetylase Sirt1 which has important roles in cell survival and as a mimic of caloric 343 
restriction which extends lifespan in many models(120).  Sirt1 is intimately involved in 344 
osteoarthritis with deletion of Sirt1 in mice causing more rapid development of osteoarthritis 345 
in a post-surgical model(121).  Resveratrol decreases osteoarthritis score when directly 346 
injected intraarticularly in the rabbit ACLT model of osteoarthritis(122; 123).  It is an NFkappaB 347 
inhibitor in chondrocytes and blocks inflammation and apoptosis(124-126).  It has also been 348 
shown to decrease proteolysis (e.g. MMPs and ADAMTSs) and enhance extracellular matrix 349 
synthesis(127).  350 
Interestingly, resveratrol has been shown to display synergistic effects on chondrocyte 351 
phenotype and apoptosis with curcumin (see below)(128; 129).  These compounds both inhibit 352 
NFkappaB, but are known to act via different mechanisms.   353 
 354 
Curcumin 355 
Curcumin is the major curcuminoid found in the spice, turmeric.  It has been shown to be an 356 
NFkappaB inhibitor(130), and used in chondrocytes as an inhibitor of oncostatin M-, IL-1- and 357 
TNFalpha-induced signalling(131-133).  Here it was shown to inhibit JNK, AP1, STAT and 358 
MAPK signalling, to inhibit expression of key MMPs in cartilage and proposed to have 359 
potential clinical utility.  Innes et al use a turmeric extract in a clinical trial of osteoarthritis in 360 
the dog, with clinical assessments showing significant improvement(134).  The anti-catabolic 361 
effects of curcumin in human articular chondrocytes were confirmed(135) and its impact 362 
extended to include anti-apoptotic activity(136), pro-anabolic effects on matrix expression(66; 363 
136)
, inhibition of COX2 expression and other inflammatory mediators(137; 138).  Efficacy was 364 
also shown in cartilage explants(66; 139) and murine models of inflammatory arthritis(140), 365 
though not yet osteoarthritis.  Curcumin itself has poor solubility and bioavailability(141), but a 366 
curcumin-phophatidylcholine complex (Meriva), designed to overcome this, has shown some 367 
efficacy in small-scale clinical trials(142; 143).  As discussed above, a thorough understanding 368 
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of mechanism of action has led to experiments showing synergy between curcumin and 369 
resveratrol(128; 129).   370 
 371 
Avocado-soybean unsaponifiables 372 
Whilst not truly dietary-derived, avocado-soybean unsaponifiables (ASU), Piascledine, has 373 
been developed by Laboratoire Expanscience and is the unsaponifiable fraction of one-third 374 
avocado oil and two-third soybean oil.  It is a mixture of tocopherols, plant sterols and other 375 
molecules(144).  A recent moderate sized trial of Piascledine in hip osteoarthritis (the 376 
ERADIAS study) over 3 years showed that whilst there was no significant difference in mean 377 
joint space width loss between treatment and placebo, there were significantly less 378 
progressors in the treatment group.  There was no difference in clinical outcomes including 379 
pain or analgesic/NSAID (non-steroidal anti-inflammatory drug) use(145).  This was somewhat 380 
similar to an earlier smaller study examining structural modification(146), but very different to 381 
other earlier trials, where ASU demonstrated reductions in pain, functional disability or 382 
NSAID use in patients with hip or knee osteoarthritis over 3-6 months(147-149).  In a dog ACLT 383 
model of osteoarthritis, ASU reduced disease severity and decreased MMP-13 384 
production(150), though in an ovine model of post-meniscectomy osteoarthritis, ASU was 385 
described to have a ‘subtle, but statistically significant’ effect on cartilage(151).  In vitro data 386 
show that ASU exhibit anti-catabolic (MMP expression), anti-inflammatory (PGE2, NO, 387 
COX2) and pro-anabolic (type II collagen and aggrecan synthesis) in chondrocytes.  It has 388 
also been shown to inhibit NFkappaB activity(152-154).  It should also be pointed out that other 389 
formulations of ASU exist and one from Nutramax has been shown to have similar in vitro 390 
activity in chondrocytes(155).  Data from equine chondrocytes suggests that this ASU can act 391 
synergistically with EGCG(156).  The relative merits of each preparation have been the subject 392 
of debate(144; 157; 158).   393 
 394 
Ginger 395 
There have been several small clinical trials exploring the efficacy of ginger extract in the 396 
treatment of osteoarthritis.  Trials using Zingiber officinale extract showed variable outcome 397 
and a review found that evidence for its efficacy in osteoarthritis was weak(159).  A mixture of 398 
extracts from Zingiber officinale and Alpinia galangal used in a short (6 week) study showed 399 
a significant effect in reducing clinical symptoms(160).  In vitro research suggests that ginger 400 
extract can decrease production of inflammatory mediators from chondrocytes(161) and 401 
synoviocytes(162). 402 
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 403 
Sulphur-containing compounds 404 
A cross-sectional study in twins demonstrated that consumption of both allium vegetables 405 
and also non-citrus fruits showed a protective association with hip osteoarthritis(163).  Further, 406 
diallyl disulphide, a compound from garlic, was shown to inhibit IL-1-induced MMP1, MMP3 407 
and MMP13 expression(163).  Diallyl sulphide has also been shown to block expression of 408 
these enzymes and ameliorate cartilage destruction when administered intraarticularly in the 409 
rabbit ACLT model of osteoarthritis(164).   410 
 411 
Others 412 
Interestingly, data on the progression of knee osteoarthritis, coming from the osteoarthritis 413 
initiative (OAI) showed that frequent soft drink consumption is associated with increased 414 
disease progression in men, independent of obesity(165).  This obviously requires replication.  415 
An extract of edible bird’s nest (which is made from swiftlet saliva), has been shown to have 416 
anti-catabolic, anti-inflammatory and pro-anabolic activity on human osteoarthritic 417 
chondrocytes(166).  Sesamin, a lignan from sesame seeds has been reported to be 418 
chondroprotective in an explant assay, decreasing MMP expression and activation(167).  An 419 
extract of a variety of mint which overexpressed rosmarinic acid inhibits LPS-induced GAG 420 
release and inflammatory mediators from porcine cartilage explants(168). 421 
 422 
Conclusions 423 
There are many compounds present in the habitual diet which have been shown to have 424 
activity in both laboratory models of osteoarthritis and/or human disease. Where examined, 425 
many of these compounds appear to be inhibitors of the NFkappaB pathway.  This signalling 426 
pathway has been shown to play a role in the development and progression of 427 
osteoarthritis(169).  Two studies suggest that using a combination of compounds which inhibit 428 
the NFkappaB pathway via different mechanisms gives a synergistic response(128; 129).  It 429 
would thus be important to understand the mode of NFkappaB inhibition for all compounds 430 
with this activity.  In order to achieve synergy, it will also be important to discover 431 
compounds which do not act via this mechanism.  Since habitual dietary intakes vary widely, 432 
an understanding of food combinations which protect the joint may be key and this may also 433 
be a means to develop specific food products or offer targeted advice to reduce risk.   434 
 14
Basic science provides information on mechanisms of cartilage protection in healthy tissue 435 
and the prevention of cartilage destruction in disease.  The design of randomised clinical 436 
trials in the longer term needs to include ‘at risk’ populations (in which incidence of OA can 437 
be used as an outcome measure), as well as patients with existing OA.  This is in line with 438 
current EFSA (European Food Standards Agency) recommendations that the design of 439 
human trials must demonstrate a preventative effect on the healthy joint, separately from an 440 
impact on established OA per se to establish claims in both areas.   441 
In summary, diet offers a route by which the health of the joint can be protected and 442 
osteoarthritis incidence or progression decreased.  In a chronic disease, with risk factors 443 
increasing in the population and with no pharmaceutical cure, an understanding of this will 444 
be crucial. 445 
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